Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 316, Issue 5, 2016, Pages 500-508

  Margulies, Kenneth B ^a   Hernandez, Adrian F ^b   Redfield, Margaret M ^c   Givertz, Michael M ^d   Oliveira, Guilherme H ^e   Cole, Robert ^f   Mann, Douglas L ^g   Whellan, David J ^h   Kiernan, Michael S ⁱ   Felker, G Michael ^j   McNulty, Steven E ^b   Anstrom, Kevin J ^b   Shah, Monica R ^k   Braunwald, Eugene ^d   Cappola, Thomas P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f EMORY UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ TUFTS UNIVERSITY   (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

6 MINUTE WALK DISTANCE TEST; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART FUNCTION; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TIME OF DEATH; TREATMENT DURATION; AGONISTS; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ODDS RATIO; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; ODDS RATIO; PATIENT READMISSION; QUALITY OF LIFE; STROKE VOLUME; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84982082404     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.10260     Document Type: Article

References (21)

1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure-associated hospitalizations in the United States. J AmColl Cardiol. 2013;61(12):1259-1267.
2. Abel ED. Myocardial insulin resistance and cardiac complications of diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(2):219-226.
3. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development ofmyocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res. 2004;61 (2):297-306.
4. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J AmColl Cardiol. 1997;30(2):527-532.
5. Grigoropoulou P, Eleftheriadou I, Zoupas C, Diamanti-Kandarakis E, Tentolouris N. Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance. Curr Diabetes Rev. 2013;9(5):412-417.
6. Clarke SJ, McCormick LM, Dutka DP. Optimising cardioprotection duringmyocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol. 2014; 13:12.
7. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694-699.
8. Velez M, Peterson EL, Wells K, et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail. 2015;21 (1):2-8.
9. Margulies KB, Anstrom KJ, Hernandez AF, et al; Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the Functional Impact of GLP-1 for Heart Failure Treatment study. Circ Heart Fail. 2014;7(4):673-679.
10. Lachin JM. Worst-rank score analysis with informativelymissing observations in clinical trials. Control Clin Trials. 1999;20(5):408-422.
11. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22): 1651-1658.
12. Anand IS, Fisher LD, Chiang YT, et al; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278-1283.
13. Scirica BM, Braunwald E, Raz I, et al; SAVOR-TIMI-53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation. 2015;132(15):e198]. Circulation. 2014;130(18):1579-1588.
14. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147-158.
15. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11): 1788-1803.
16. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222-230.
17. Zannad F, Cannon CP, Cushman WC, et al; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: amulticentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076.
18. Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
19. Pfeffer MA, Claggett B, Diaz R, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-2257.
20. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
21. Marso SP, Poulter NR, Nissen SE, et al. Design of the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. Am Heart J. 2013;166(5):823-30.e5, e825.